Rituximab 500mg/50mL Infusion$516.00
1–9 boxes
$516.00 each
10–24 boxes
8% off
25+ boxes
10% off
Rituximab 500mg/50mL Infusion
SKU GME1329Oncology Care
Product Introduction
Rituximab 500mg/50mL is an anti-CD20 monoclonal antibody used for certain B-cell lymphomas and chronic lymphocytic leukaemia. It is also used for rheumatoid arthritis and selected vasculitic or autoimmune disorders.
How to use
The diluted medicine is administered by intravenous infusion. Premedication and a gradual initial infusion rate reduce reaction risk. Vital signs are monitored, particularly during the first infusion.
How it works
Rituximab binds CD20 on B cells and promotes their removal through immune-mediated mechanisms.
Side effects
Infusion reactions, fever, chills, fatigue, infections and low blood counts can occur. Severe skin reactions and hepatitis B reactivation are important risks.
Important information
Hepatitis B screening and baseline blood counts precede treatment. Vaccinations should be planned in advance because response can be reduced after B-cell depletion.
Uses
- Selected CD20-positive lymphomas and CLL, rheumatoid arthritis and certain vasculitic or autoimmune disorders.
Benefits
Can reduce B-cell cancer activity and the immune-driven inflammation responsible for symptoms in autoimmune disease.
Why is the first infusion often slower?
Infusion reactions are most frequent early in treatment. A gradual rate allows early detection and management.
What if I develop new weakness, confusion or problems with balance after rituximab?
Seek urgent medical assessment, including after treatment has finished. Rare progressive multifocal leukoencephalopathy, a serious brain infection, can cause new weakness, confusion, speech changes, impaired balance or altered vision.
Can vaccines be less effective afterwards?
Yes. B-cell depletion can reduce the antibody response, so timing is planned around treatment.
Why is a past hepatitis B infection relevant?
The virus can reactivate during or after B-cell depletion even if the earlier infection seemed resolved.
CD20: a marker on many B lymphocytes. B cell: a white blood cell involved in antibody production. Monoclonal antibody: a targeted laboratory-produced antibody.; AR: Rituximab 500mg/50mL تسريب وريدي; FR: Rituximab 500mg/50mL perfusion intraveineuse; PT: Rituximab 500mg/50mL infusão intravenosa; ES: Rituximab 500mg/50mL perfusión intravenosa; RU: Rituximab 500mg/50mL внутривенная инфузия; ID: Rituximab 500mg/50mL infus intravena; VI: Rituximab 500mg/50mL thuốc truyền tĩnh mạch; MS: Rituximab 500mg/50mL infusi intravena; TL: Rituximab 500mg/50mL pagbubuhos sa ugat; ZH-SG: Rituximab 500mg/50mL 静脉输注